These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31233548)

  • 1. Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.
    Jarrard WE; Schultz A; Etheridge T; Damodaran S; Allen GO; Jarrard D; Yang B
    PLoS One; 2019; 14(6):e0218950. PubMed ID: 31233548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.
    Yang B; Etheridge T; McCormick J; Schultz A; Khemees TA; Damaschke N; Leverson G; Woo K; Sonn GA; Klein EA; Fumo M; Huang W; Jarrard DF
    Clin Epigenetics; 2019 Nov; 11(1):168. PubMed ID: 31779677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer.
    Yang B; Bhusari S; Kueck J; Weeratunga P; Wagner J; Leverson G; Huang W; Jarrard DF
    Neoplasia; 2013 Apr; 15(4):399-408. PubMed ID: 23555185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic field alterations in non-tumor prostate tissues detect prostate cancer in urine.
    Khemees TA; Yang B; Schultz A; Allen GO; Gawdzik J; Nihal A; Richards KA; Abel EJ; Jarrard DF
    Am J Clin Exp Urol; 2021; 9(6):479-488. PubMed ID: 34993267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
    Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
    Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLA2G16 is a mutant p53/KLF5 transcriptional target and promotes glycolysis of pancreatic cancer.
    Xia W; Bai H; Deng Y; Yang Y
    J Cell Mol Med; 2020 Nov; 24(21):12642-12655. PubMed ID: 32985124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.
    Møller M; Strand SH; Mundbjerg K; Liang G; Gill I; Haldrup C; Borre M; Høyer S; Ørntoft TF; Sørensen KD
    Sci Rep; 2017 Jan; 7():40636. PubMed ID: 28084441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic markers of urothelial cancer based on DNA methylation analysis.
    Chihara Y; Kanai Y; Fujimoto H; Sugano K; Kawashima K; Liang G; Jones PA; Fujimoto K; Kuniyasu H; Hirao Y
    BMC Cancer; 2013 Jun; 13():275. PubMed ID: 23735005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
    Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
    J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.
    Brikun I; Nusskern D; Decatus A; Harvey E; Li L; Freije D
    Clin Epigenetics; 2018; 10():91. PubMed ID: 29988684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.
    Connell SP; O'Reilly E; Tuzova A; Webb M; Hurst R; Mills R; Zhao F; Bapat B; Cooper CS; Perry AS; Clark J; Brewer DS
    Prostate; 2020 May; 80(7):547-558. PubMed ID: 32153047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PLA2G16 Expression in Human Osteosarcoma Is Associated with Pulmonary Metastasis and Poor Prognosis.
    Liang S; Ren Z; Han X; Yang J; Shan L; Li L; Wang B; Zhang Q; Mu T; Chen K; Xiong S; Wang G
    PLoS One; 2015; 10(5):e0127236. PubMed ID: 25993412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the epigenetic field defect to detect prostate cancer in biopsy negative patients.
    Truong M; Yang B; Livermore A; Wagner J; Weeratunga P; Huang W; Dhir R; Nelson J; Lin DW; Jarrard DF
    J Urol; 2013 Jun; 189(6):2335-41. PubMed ID: 23159584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The investigation of GSTP1, APC and RASSF1 gene promoter hypermethylation in urine DNA of prostate-diseased patients.
    Haluskova J; Lachvac L; Nagy V
    Bratisl Lek Listy; 2015; 116(2):79-82. PubMed ID: 25665470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating liquid biopsies for methylomic profiling of prostate cancer.
    Silva R; Moran B; Russell NM; Fahey C; Vlajnic T; Manecksha RP; Finn SP; Brennan DJ; Gallagher WM; Perry AS
    Epigenetics; 2020; 15(6-7):715-727. PubMed ID: 32000564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
    Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
    Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
    Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
    Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
    Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
    Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO; Topaloglu O; Begum S; Henrique R; Rosenbaum E; Van Criekinge W; Westra WH; Sidransky D
    J Clin Oncol; 2005 Sep; 23(27):6569-75. PubMed ID: 16170165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.